| Literature DB >> 28620161 |
Elias Walter1, Franziska Vielmuth1, Lukas Rotkopf1, Miklós Sárdy2, Orsolya N Horváth2, Matthias Goebeler3, Enno Schmidt4, Rüdiger Eming5, Michael Hertl5, Volker Spindler6, Jens Waschke7.
Abstract
Pemphigus is an autoimmune blistering skin disease caused primarily by autoantibodies against desmoglein (Dsg)1 and 3. Here, we characterized the mechanisms engaged by pemphigus IgG from patients with different clinical phenotypes and autoantibody profiles. All pemphigus vulgaris (PV) and pemphigus foliaceus (PF) IgG and AK23, a monoclonal mouse antibody against Dsg3, caused loss of cell cohesion, cytokeratin retraction and p38MAPK activation. Strong alterations in Dsg3 distribution were caused by mucosal (aDsg3 antibodies), mucocutaneous (aDsg1 + aDsg3) as well as atypical (aDsg3) PV-IgG. All PV-IgG fractions and AK23 compromised Dsg3 but not Dsg1 binding and enhanced Src activity. In contrast, rapid Ca2+ influx and Erk activation were induced by mucocutaneous PV-IgG and pemphigus foliaceus (PF) IgG (aDsg1) whereas cAMP was increased by mucosal and mucocutaneous PV-IgG only. Selective inhibition of p38MAPK, Src or PKC blocked loss of keratinocyte cohesion in response to all autoantibody fractions whereas Erk inhibition was protective against mucocutaneous PV-IgG and PF-IgG only. These results demonstrate that signaling patterns parallel the clinical phenotype as some mechanisms involved in loss of cell cohesion are caused by antibodies targeting Dsg3 whereas others correlate with autoantibodies against Dsg1. The concept of key desmosome regulators may explain observations from several experimental models of pemphigus.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28620161 PMCID: PMC5472593 DOI: 10.1038/s41598-017-03697-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Antibody profiles of IgG-fractions determined by Dsg1 and Dsg3 ELISA and their clinical phenotypes.
| ELISA Score | Phenotype | ||
|---|---|---|---|
| anti-Dsg3 U/ml | anti-Dsg1 U/ml | ||
| c-IgG | — | — | healthy control |
| m-PV | 2391.0 | — | mucosal |
| m-PV2 | 162.9 | — | mucosal |
| at-PV | 153.4 | — | atypical cutaneous |
| mc-PV | 225.5 | 218.8 | mucocutaneous |
| mc-PV2 | 172.5 | 154.8 | mucocutaneous |
| PF | — | 1645.0 | cutaneous |
| PF2 | — | 266.4 | cutaneous |
Figure 1Structural changes in keratinocytes after 24 h of IgG treatment. HaCaT keratinocytes stably expressing CK5-YFP were exposed to different IgG fractions for 24 h. Images shown are representatives of four independent experiments. Dsg3 staining (a–f) and CK5 expression (g–l) after IgG treatment. (m–r) Merged images of Dsg3 staining and CK5-YFP. (s–x) CK5 fluorescence intensity of a 100 pixel long line placed centrally over the cell membrane (n = 4). (y) Analysis of the distance between fluorescence peaks shown in (s–x) in μm (n = 4, *p ≤ 0.05 vs. c-IgG). Bar represents 10 μm.
Figure 2Signaling pathways activated by different IgG fractions. (a) Triton fractionation of HaCaT lysates into a TX-100 insoluble cytoskeletal and a TX-100 soluble non-cytoskeletal pool. Representative cropped Western blots of p38MAPK, src and Erk activity for each pool. (b) Densitometric analysis of signaling molecule phosphorylation normalized to the total amount in percent of control (n = 5–14, *p ≤ 0.05 vs. c-IgG). (c) Erk activation after inhibition of PKC by Bim-X and subsequent incubation of mc-PV and PF-IgG for 30 min. (d) Densitometric analysis of Erk phosphorylation corresponding to c (n = 4, *p ≤ 0.05 vs. respective c-IgG condition). Ratiometric fluorescent intensity measurement of Fura-2-AM at 340/380 nm normalized to baseline. (e) Graphs of c-IgG and PF-IgG to illustrate experimental setup. IgG incubation started at 20 s (arrow) and (f) concentrations were analyzed 60 s afterwards (dotted line) (n = 3, *p ≤ 0.05 vs. c-IgG). (g) Measurement of intracellular cAMP concentrations in keratinocytes after 6 h of IgG treatment (n = 4; *p ≤ 0.05 vs. c-IgG).
Figure 3Inhibition of Dsg3 but not Dsg1 homophilic interactions by pemphigus autoantibodies. Cell free atomic force microscopy measurements on a coated mica sheet with an AFM tip functionalized with either recombinant Dsg1-Fc or Dsg3-Fc respectively. A grid with 10 × 10 points (2.5 × 2.5 μm) was measured 5 times followed by incubation with IgG-fractions, AK23 or the mouse monoclonal Dsg1 antibody p124. The identical area was scanned again and normalized to the respective measurement before incubation (n = 3–5, *p ≤ 0.05 vs. c-IgG).
Figure 4Adhesion measurements with modulation of signaling molecules. Dispase-based dissociation assays in HaCaT keratinocytes after applying the specific inhibitors SB202190 (p38MAPK), Bim-X (PKC), U0126 (Erk) or PP2 (Src) for 1 h, followed by either (a) 24 h incubation of IgG fractions or (c) 2 h incubation of IgG fractions (n = 4; *p ≤ 0.05 vs. c-IgG with the respective mediator). (b,d) Representative images of monolayers incubated with 10 μm MTT to visualize cell fragments.
Figure 5Signaling patterns associated with autoantibody profiles. Summary (a) and schematic (b) representation of signaling patterns associated with different autoantibody fractions and their respective clinical phenotypes.